The Company entered into a Sales Agreement with A.G.P./Alliance Global Partners, as sales agent, pursuant to which the Company may offer and sell, from time to time, through A.G.P., up to $65,000,000…
At September 30, 2025 and December 31, 2024, the Company recorded a payable to AmplifyBio of $26,000 and $0, respectively, for medical research performed on behalf of the Company.
Under the terms of the Amended and Restated Agreement, AN will be entitled to a royalty of 2% on net sales of each Product, as defined in the Amended and Restated Agreement
During April 2025, the Company’s wholly-owned subsidiary, INmune Bio International. Ltd., entered into a 2-year collaboration agreement with a vendor whereby it makes fixed payments to the vendor in …
In addition, AN will be entitled to fees equal to £400 plus VAT in respect of the Cell and Gene Therapies Services, as defined in the Amended and Restated Agreement, related to each umbilical cord tissue
INmune Bio Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INMB-DEBT-10290
Warrants outstanding: 1557592
90%
xbrl warrant detail from xbrl 2025-12-31.
INMB-DEBT
Debt stack $1.5M
90%
Market cache reports total debt of $1.5M.
INMB-DEBT-10291
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-12-31.
INmune Bio Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for INmune Bio Inc..
INmune Bio Inc. Ownership
Holder
Name
Confidence
Evidence
INMB-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 82 tracked holders.
INmune Bio Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
